Novo Nordisk receives FDA approval for FlexTouch® in the US

Novo Nordisk receives FDA approval for FlexTouch® in the US

Copenhagen, Denmark, 1 November 2013 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the prefilled insulin pens NovoRapid® FlexTouch® and Levemir® FlexTouch®.
Also, Levemir® FlexTouch® has just been approved by the Canadian health authorities, Health Canada.
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk. When a dose is dialled with traditional prefilled pens, the push button extends, and at larger doses this can present challenges for the patient1,2. The spring-loaded dosing mechanism of FlexTouch® ensures the push button does not extend at any dose and patients can easily deliver their insulin dose with just a touch of a button1,2.
"Novo Nordisk is committed to continuously developing new and better solutions within insulin delivery, and this approval is an important milestone in the efforts to make the lives of people with diabetes easier", said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.
NovoRapid® is the most prescribed rapid-acting insulin analogue worldwide3 while Levemir® is a long-acting basal insulin, both have been developed by Novo Nordisk. Novo Nordisk plans to make FlexTouch® available in the US within the next year. FlexTouch® was approved by the European Commission in July 2011 and launched in several countries including the United Kingdom, Denmark and Japan during the last couple of years. NovoRapid® FlexTouch® was launched in Canada in May 2012.
Further information
Katrine Sperling
+45 4442 6718
Sarah Spielvogel (US)
(+1) 609 240 5333
Kasper Roseeuw Poulsen
+45 4442 4303
Frank Daniel Mersebach
Daniel Bohsen
+45 4442 0604
+45 3079 6376
Lars Borup Jacobsen
+45 3075 3479
Jannick Lindegaard (US)
+1 609 786 4575
1. Oyer et al. Expert Opinion on Drug Delivery, 2011;8(10):1259-1269
2. Schipper et al. Current Medical Research & Opinion, 2012;28(8):1297-1303
3. IMS Health Inc. IMS MIDAS, February 2013


Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.